Development of a Personalized Tobacco Cessation Intervention Package (PTCIP) for Persons with Schizophrenia in India.
Stage-based
content validity
intervention
nonpharmacological
schizophrenia
tobacco cessation
Journal
Indian journal of psychological medicine
ISSN: 0253-7176
Titre abrégé: Indian J Psychol Med
Pays: United States
ID NLM: 7910727
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
ppublish
Résumé
Among persons with schizophrenia (PwS), tobacco use is higher in comparison to the general population, contributing to greater morbidity and mortality. Pharmacological interventions combined with psychosocial interventions are effective in tobacco cessation. While the effectiveness of extant psychosocial interventions-when used in isolation-seems limited, developing better combinations of interventions could help treatment providers deliver tobacco cessation services to PwS at different stages of motivation to quit. We aimed to develop a personalized tobacco cessation intervention package (PTCIP) for PwS. The stage-based intervention package was developed through a systematic review of interventions for tobacco cessation, the authors' clinical experience, and expert validation. The components of the intervention package, developed for PwS visiting the outpatient psychiatric department, were retained, removed, or added based on the content validity ratio (CVR). The final components included brief advice, principles of motivational interviewing, psychoeducation, decisional balance matrix, positive reinforcement, offering various treatment options, personalized feedback using a smoking-risk calculator, and prediction of cardiovascular risk using the WHO package of essential noncommunicable disease (PEN). The delivery of the intervention package was refined based on pilot testing in eight participants. The tailored package was designed to be delivered by a mental health professional as a single comprehensive 40 min to 45 min face-to-face session, integrated with routine follow-up visits, followed by two telephonic conversations in the second and third week of the initial session. The package needs to be tested in a randomized controlled trial for its effectiveness.
Sections du résumé
Background
UNASSIGNED
Among persons with schizophrenia (PwS), tobacco use is higher in comparison to the general population, contributing to greater morbidity and mortality. Pharmacological interventions combined with psychosocial interventions are effective in tobacco cessation. While the effectiveness of extant psychosocial interventions-when used in isolation-seems limited, developing better combinations of interventions could help treatment providers deliver tobacco cessation services to PwS at different stages of motivation to quit. We aimed to develop a personalized tobacco cessation intervention package (PTCIP) for PwS.
Methods
UNASSIGNED
The stage-based intervention package was developed through a systematic review of interventions for tobacco cessation, the authors' clinical experience, and expert validation. The components of the intervention package, developed for PwS visiting the outpatient psychiatric department, were retained, removed, or added based on the content validity ratio (CVR).
Results
UNASSIGNED
The final components included brief advice, principles of motivational interviewing, psychoeducation, decisional balance matrix, positive reinforcement, offering various treatment options, personalized feedback using a smoking-risk calculator, and prediction of cardiovascular risk using the WHO package of essential noncommunicable disease (PEN). The delivery of the intervention package was refined based on pilot testing in eight participants.
Conclusion
UNASSIGNED
The tailored package was designed to be delivered by a mental health professional as a single comprehensive 40 min to 45 min face-to-face session, integrated with routine follow-up visits, followed by two telephonic conversations in the second and third week of the initial session. The package needs to be tested in a randomized controlled trial for its effectiveness.
Identifiants
pubmed: 36925498
doi: 10.1177/02537176221105581
pii: 10.1177_02537176221105581
pmc: PMC10011849
doi:
Types de publication
Journal Article
Langues
eng
Pagination
132-138Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declared no potential conflicts of interest concerning this article’s research, authorship, and publication.
Références
Lancet Psychiatry. 2019 Jan;6(1):2-3
pubmed: 30527762
BMJ. 1997 Aug 9;315(7104):361-3
pubmed: 9270462
J Consult Clin Psychol. 2004 Aug;72(4):723-8
pubmed: 15301657
Health Educ Res. 2005 Apr;20(2):244-58
pubmed: 15618324
BMJ. 2014 Feb 13;348:g1151
pubmed: 24524926
Clin Med (Lond). 2020 Nov;20(6):551-559
pubmed: 33199319
Addict Behav. 2005 Aug;30(7):1290-9
pubmed: 16022927
Tob Use Insights. 2016 Mar 10;9:7-12
pubmed: 26997871
Am J Psychiatry. 2006 Nov;163(11):1934-42
pubmed: 17074945
BMJ. 2013 Feb 26;346:f540
pubmed: 23444423
J Nerv Ment Dis. 2012 Feb;200(2):142-6
pubmed: 22297311
Psychiatr Danub. 2009 Sep;21(3):371-5
pubmed: 19794359
BMJ. 2003 May 31;326(7400):1175-7
pubmed: 12775617
Nicotine Tob Res. 2016 Mar;18(3):243-50
pubmed: 25744954
J Clin Psychiatry. 2008 Nov;69(11):1743-50
pubmed: 19026259
J Pediatr. 2008 Sep;153(3):414-9
pubmed: 18534619
Am J Addict. 2009 Sep-Oct;18(5):386-92
pubmed: 19874158
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
Encephale. 2019 Sep;45(4):345-356
pubmed: 31153585
Acta Psychiatr Scand. 2015 May;131(5):333-41
pubmed: 25559296
N Engl J Med. 2010 Jun 17;362(24):2295-303
pubmed: 20554984
BMJ. 2010 Apr 27;340:c1900
pubmed: 20423957
Prim Care. 1999 Sep;26(3):611-31
pubmed: 10436290
PLoS Med. 2005 May;2(5):e141
pubmed: 15916472
Am J Psychiatry. 1998 Jul;155(7):974-6
pubmed: 9659869
Int J Prev Med. 2016 Jan 11;7:7
pubmed: 26941908
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
Lancet Psychiatry. 2019 May;6(5):379-390
pubmed: 30975539
Addiction. 2006 Apr;101(4):590-8
pubmed: 16548938
Addict Behav. 2001 Jul-Aug;26(4):583-602
pubmed: 11456079
Front Psychiatry. 2018 Nov 06;9:565
pubmed: 30459658
BMJ Open. 2016 Apr 20;6(4):e010795
pubmed: 27098825
Front Psychiatry. 2018 Dec 06;9:672
pubmed: 30574101
Am Psychol. 1992 Sep;47(9):1102-14
pubmed: 1329589
Nicotine Tob Res. 2020 Jan 27;22(1):48-57
pubmed: 31289809
Brain Behav. 2013 May;3(3):302-26
pubmed: 23785661
J Epidemiol Community Health. 2016 May;70(5):520-5
pubmed: 26573236
Am J Psychiatry. 2020 Sep 1;177(9):868-872
pubmed: 32867516
J Consult Clin Psychol. 1991 Apr;59(2):295-304
pubmed: 2030191
PLoS One. 2014 Nov 24;9(11):e113013
pubmed: 25419703
Public Health. 2001 Sep;115(5):328-37
pubmed: 11593442
Br J Health Psychol. 2020 Sep;25(3):615-638
pubmed: 32678937
J Gen Intern Med. 2007 Feb;22(2):223-7
pubmed: 17356990
J Subst Abuse Treat. 2014 Mar;46(3):346-55
pubmed: 24210533
Asian J Psychiatr. 2021 Feb;56:102530
pubmed: 33465747
Cochrane Database Syst Rev. 2010 Nov 10;(11):CD004492
pubmed: 21069681
Schizophr Res. 2017 May;183:124-129
pubmed: 27956009
Am J Public Health. 2006 Oct;96(10):1808-14
pubmed: 17008577
Addict Behav. 2009 Apr;34(4):365-73
pubmed: 19097706
Addiction. 2002 Sep;97(9):1171-82
pubmed: 12199833
J Epidemiol Community Health. 2002 Feb;56(2):119-27
pubmed: 11812811